. "http://www.isvav.cz/projectDetail.do?rowId=NT13046"^^ . . . "Kardiovaskul\u00E1rn\u00ED \u00FA\u010Dinky inkretinov\u00E9 l\u00E9\u010Dby diabetes mellitus 2.typu" . . . "2014-03-21+01:00"^^ . "P\u0159edm\u011Btem \u0159e\u0161en\u00ED projektu je identifikace mechanizm\u016F kardioprotektivn\u00EDho vlivu GLP-1 agonist\u016F. Bude srovn\u00E1v\u00E1na l\u00E9\u010Dba jednotliv\u00FDmi GLP-1 agonisty (exenatid, liraglutid) a jej\u00ED vliv na kardiovaskul\u00E1rn\u00ED rizikov\u00E9 faktory. Projekt je zalo\u017Een na dlouhodob\u00E9m sledov\u00E1n\u00ED diabetik\u016F s nov\u011B nasazenou l\u00E9\u010Dbou GLP-1 agonisty. Bude vy\u0161et\u0159eno celkem 90 pacient\u016F s diabetes mellitus 2. typu a obezitou. Budou randomizov\u00E1ni k l\u00E9\u010Db\u011B exenatidem, nebo liraglutidem. Kontroln\u00ED skupinu budou tvo\u0159it diabetici l\u00E9\u010Den\u00ED standardn\u00ED kombinovanou antidiabetickou l\u00E9\u010Dbou bez GLP-1 agonist\u016F. Pacienti budou vy\u0161et\u0159eni vstupn\u011B a po prvn\u00EDm roce. Bude provedeno fyzik\u00E1ln\u00ED vy\u0161et\u0159en\u00ED a sledov\u00E1ny parametry kompenzace DM, sonografick\u00E9 vy\u0161et\u0159en\u00ED karotid, echokardiografick\u00E9 vy\u0161et\u0159en\u00ED, monitorace krevn\u00EDho tlaku, vy\u0161et\u0159eny mechanick\u00E9 vlastnosti tepen, d\u00E1le stanoveny humor\u00E1ln\u00ED markery endoteli\u00E1ln\u00ED dysfunkce a proz\u00E1n\u011Btliv\u00E9 cytokiny ." . . "2015-01-22+01:00"^^ . "0"^^ . "2012-04-01+02:00"^^ . . "1"^^ . . . "0"^^ . "1"^^ . " endothelial dysfunction" . "diabetes mellitus; endothelial dysfunction; atherosclerosis; glucagon-like peptide-1 agonis"@en . . "1"^^ . . "diabetes mellitus" . . . " atherosclerosis" . "2015-12-30+01:00"^^ . . . "The aim of the project is to identify the mechanisms of cardioprotective effects of GLP-1 agonists. Two GLP-1 agonists (exenatide and liraglutide) and their influence on cardiovascular risk factors will be evaluated in a head-to-head comparison. The project is based on a long-term follow-up of type 2 diabetic patients treated with GLP-1 agonists. In total, 90 patients with T2DM will be included. The patients will be randomized for either exenatide or liraglutide therapy. The control group will consist of type 2 diabetics treated with standard anti-diabetic combination therapy without GLP-1 agonists or DPP-4 inhibitors. Patients will be examined before the start of GLP-1-based therapy and after 1st year of treatment. A physical examination, ultrasound examination of carotid arteries and echocardiography will be performed and cicrulating markers of endothelial dysfunction will be determined."@en . . . "Cardiovascular effects of incretin therapy in type 2 diabetes mellitus"@en . "NT13046" .